AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04350398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.
Study NCT04350398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional therapy
Description: Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
Study NCT00186147 — intervention group
Intervention type: PROCEDURE
Intervention: collection and storage of tissue samples for research
Description: Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
Study NCT00615433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 120mg/day
Study NCT00615433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 15mg/day
Study NCT00615433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebor Comparator
Study NCT00615433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg tablets
Description: Lurasidone 40 mg tablets
Study NCT02714634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate + targeted therapy administration
Description: * Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib
Study NCT02714634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
Study NCT00958529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin Fiber Supplement
Description: Orange juice fortified with 0, 5g, and 10g of 2 inulin products
Study NCT02688920 — intervention group
Intervention type: PROCEDURE
Intervention: EUS and OCT imaging
Description: Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
Study NCT04250974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture with electricity
Study NCT04250974 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: acupuncture with electricity
Study NCT05328232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
Study NCT01663831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mosquito topical repellent
Description: Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
Study NCT03849612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID system
Study NCT03849612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study NCT02603640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scanning
Study NCT01623687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Component for acetabulum (Regenerex RingLoc cup)
Description: A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
Study NCT01623687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Components for the acetabulum (Lubinus cross linked cup)
Description: cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
Study NCT01623687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty components are for the femur (Cemented Lubinus SP II stem)
Description: Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
Study NCT00937391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-6661)
Description: For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
Study NCT04151342 — intervention group
Intervention type: DRUG
Intervention: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
Description: Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
Study NCT04151342 — intervention group
Intervention type: OTHER
Intervention: Patient-reported outcomes (PROs)
Description: Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
Study NCT02750215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib (INC280)
Description: treatment with Capmatinib (INC280)
Study NCT00575250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Osteoporosis Prevention and Self-Management Course
Description: Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
Study NCT00575250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Introductory education session on osteoporosis
Description: Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
Study NCT04101201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: µSmin® Plus
Description: µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
Study NCT04101201 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
Study NCT01990144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine+Rituximab
Description: Patients will receive :~* Rituximab 375 mg/m2 intravenously on day 1\*~* Bendamustine 90 mg/m2 intravenously on days 2 and 3\*\* Treatment will be administered on a 28-day cycle basis.~  * Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~    * After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice.
Study NCT01505647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live (AMP)
Description: One approximately 0.65-mL injection subcutaneously on Day 1
Study NCT01505647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zoster Vaccine, Live
Description: One approximately 0.65-mL injection subcutaneously on Day 1
Study NCT04215133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
Study NCT02300727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Curcumin-MTD
Description: 0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
Study NCT02300727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash-standard pharmacy preparation
Description: Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.
Study NCT02300727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
Study NCT03464695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
Study NCT02859506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory quotient
Study NCT02859506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory quotient
Study NCT02859506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory quotient
Study NCT02859506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olfactory liking
Study NCT02859506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olfactory liking
Study NCT02859506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory liking
Study NCT02691962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xen Matrix AB
Description: Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
Study NCT04220853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rhinomanometry in patients after septoplasty and/or turbinoplasty
Description: Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
Study NCT04220853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry in patients after septoplasty and/or turbinoplasty
Description: Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
Study NCT00596362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVASTIN
Description: a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
Study NCT03094039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilatory support while attached to the cord
Description: Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
Study NCT03094039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
Study NCT01574079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
Study NCT01574079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy plus Mirror Therapy
Description: The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
Study NCT01623687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty components are for the femur (Corail stem)
Description: Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson \& Johnsson, USA).
Study NCT01421849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Denture implantation
Description: In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months.
Study NCT02865343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT02491060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121 Lotion
Description: Investigational Product: IDP-121 Lotion
Study NCT02491060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-121 Vehicle Lotion
Description: Comparator Product: IDP-121 Vehicle Lotion
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI - Stroop task
Description: 2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI - MID task
Description: 2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Signal Task
Description: Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCID-II
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDQ
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASRS
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AQ
Description: See Detailed Study Description.
Study NCT02865343 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Non-invasive ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT03283982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Ventral Hernia Repair with IPOM
Description: Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
Study NCT03283982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Ventral Hernia Repair with IPOM
Description: Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
Study NCT04319679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: 6 times during 2 weeks
Study NCT04319679 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: 6 times during 2 weeks
Study NCT02043379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
Study NCT00211562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, Omega 3, Vitamin E+C
Description: No adverse event nor SAE noted.
Study NCT02089282 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Study NCT02955628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib-RICE
Description: Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
Study NCT03093025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-121 10 mg
Description: Orally taken once daily
Study NCT03093025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-121 50 mg
Description: Orally taken once daily
Study NCT03093025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally taken once daily
Study NCT02863822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet
Description: Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
Study NCT02863822 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choose My Plate Diet
Description: Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
Study NCT02043379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
Study NCT04153071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPUS system
Description: Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
Study NCT00657826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm
Description: Isolated aortic valve replacement with a size 19mm valve